Homology Medicines, Inc. (FIXX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Homology Medicines, Inc. (FIXX) trades at $0.93 with AI Score 51/100 (Grade B). Homology Medicines, Inc. is a genetic medicines company focused on developing treatments for rare genetic diseases. Market cap: $3.02M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for FIXX: FIXX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FIXX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
FIXX: 3/7 perspectives are bearish. Dominant signal: Moon AI bullish.
How is this calculated? →Homology Medicines, Inc. (FIXX) Healthcare & Pipeline Overview
Homology Medicines, Inc. pioneers genetic medicines for rare diseases, leveraging its AAVHSc platform for in vivo gene therapy and editing. With a focus on single-injection treatments targeting various tissues, the company advances clinical programs like HMI-102 for PKU, positioning itself in the competitive biotechnology landscape.
What Is the Investment Thesis for FIXX?
Homology Medicines presents a focused investment opportunity within the genetic medicine space, specifically targeting rare genetic diseases. The company's proprietary AAVHSc platform offers a differentiated approach to in vivo gene therapy and editing. The ongoing Phase 2 clinical trial for HMI-102 in adults with PKU represents a near-term catalyst. Successful clinical trial outcomes and subsequent regulatory approvals could drive significant value. The company's pipeline, including HMI-103, HMI-202, HMI-203, and HMI-104, provides additional growth potential. However, the company faces risks associated with clinical trial success, regulatory hurdles, and competition from other gene therapy companies. The current market capitalization of $3.02M may reflect investor concerns about these risks, but also presents an opportunity for significant upside if the company achieves its clinical and regulatory milestones.
Based on FMP financials and quantitative analysis
FIXX Key Highlights
- Gross Margin of 99.5% indicates efficient cost management in research and development activities.
- Profit Margin of 61.9% suggests effective monetization of existing assets and intellectual property.
- Phase 2 clinical trial of HMI-102 for PKU in adults represents a key milestone with potential for significant value creation.
- AAVHSc platform offers a differentiated approach to in vivo gene therapy and editing, potentially leading to more effective treatments.
- Market Cap of $3.02M may indicate undervaluation relative to pipeline potential, but also reflects risks associated with clinical trials and regulatory approvals.
Who Are FIXX's Competitors?
FIXX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLUE bluebird bio, Inc. | $4.97 | +0.00% | $48.67M | 67 |
| SRPT Sarepta Therapeutics | $19.59 | +2.14% | $2.07B | 39 |
| ANAB AnaptysBio, Inc. | $67.29 | +8.00% | $2.90B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $23.12 | +4.69% | $2.05B | 79 |
| ABCL AbCellera Biologics Inc. | $7.69 | -2.29% | $2.35B | 76 |
| CGEN Compugen Ltd. | $2.38 | +1.06% | $225.51M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $24.32 | +4.58% | $1.58B | 68 |
| IVBXF Innovent Biologics, Inc. | $10.15 | -13.05% | $17.61B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FIXX's Key Strengths?
- Proprietary AAVHSc platform
- Focus on rare genetic diseases
- Strong intellectual property portfolio
- Experienced management team
What Are FIXX's Weaknesses?
- Limited financial resources
- Dependence on clinical trial success
- Small number of employees
- Early stage of development
What Could Drive FIXX Stock Higher?
- Phase 2 pheNIX clinical trial results for HMI-102 in adults with PKU.
- Potential regulatory submissions for HMI-102 following successful clinical trial results.
- Continued advancement of HMI-103, HMI-202, HMI-203, and HMI-104 through preclinical and clinical development.
What Are the Key Risks for FIXX?
- Financial-distress signal — its Altman Z-Score of -2.19 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for HMI-102 or other pipeline programs.
- Regulatory delays or rejections for its gene therapies.
- Competition from other gene therapy companies.
- Product liability claims related to its gene therapies.
- Dependence on raising additional capital to fund its operations.
What Are the Growth Opportunities for FIXX?
- Expansion into new therapeutic areas: Homology Medicines can leverage its AAVHSc platform to develop treatments for additional rare genetic diseases beyond its current pipeline. The market for rare disease therapies is substantial, with increasing regulatory support and pricing flexibility. Identifying and validating new targets for its platform could significantly expand the company's addressable market. This expansion could take 3-5 years, requiring significant investment in research and development.
- Partnerships and collaborations: Collaborating with larger pharmaceutical companies or academic institutions could provide Homology Medicines with access to additional resources, expertise, and funding. Strategic partnerships could accelerate the development and commercialization of its pipeline products. This could involve licensing agreements, joint ventures, or co-development arrangements. Such partnerships could materialize within the next 1-2 years.
- Geographic expansion: Homology Medicines can expand its geographic reach by seeking regulatory approvals and commercializing its products in new markets, such as Europe and Asia. The global market for gene therapies is growing rapidly, and expanding into new regions could significantly increase the company's revenue potential. This expansion would likely occur within 3-5 years after initial product approvals.
- Advancement of pipeline programs: The successful advancement of its pipeline programs, including HMI-103, HMI-202, HMI-203, and HMI-104, represents a significant growth opportunity for Homology Medicines. Positive clinical trial results and regulatory approvals for these programs could drive substantial value creation. The timelines for these programs vary, with some potentially reaching the market within the next 3-5 years.
- Improved AAVHSc platform: Continued refinement and improvement of the AAVHSc platform could enhance its safety, efficacy, and targeting capabilities. This could lead to the development of more effective gene therapies with broader applications. Investing in research and development to optimize the platform is crucial for maintaining a competitive advantage. This is an ongoing process with continuous improvements expected over time.
What Opportunities Does FIXX Have?
- Expansion into new therapeutic areas
- Partnerships and collaborations
- Geographic expansion
- Advancement of pipeline programs
What Threats Does FIXX Face?
- Competition from other gene therapy companies
- Regulatory hurdles
- Clinical trial failures
- Product liability claims
What Are FIXX's Competitive Advantages?
- Proprietary AAVHSc platform: Homology Medicines' AAVHSc platform provides a differentiated approach to in vivo gene therapy and editing.
- Intellectual property: The company has a strong intellectual property portfolio protecting its AAVHSc platform and gene therapy candidates.
- Expertise in gene therapy: Homology Medicines has a team of experienced scientists and clinicians with expertise in gene therapy development.
What Does FIXX Do?
Homology Medicines, Inc., founded in 2015 and headquartered in Bedford, Massachusetts, is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases. The company's core innovation lies in its proprietary adeno-associated virus vector (AAVHSc) platform. This platform enables the delivery of genetic medicines in vivo, utilizing both gene therapy and nuclease-free gene editing techniques. Homology Medicines' AAVHSc vectors are designed to target a range of disease-relevant tissues through a single injection, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. The company's lead product candidate is HMI-102, a gene therapy currently in Phase 2 pheNIX clinical trial for the treatment of phenylketonuria (PKU) in adults. In addition to HMI-102, Homology Medicines is developing HMI-103 for the treatment of PKU in pediatric patients, HMI-202 for metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 for paroxysmal nocturnal hemoglobinuria. Homology Medicines aims to address the unmet needs of patients with rare genetic diseases through its innovative gene therapy and gene editing approaches.
What Products and Services Does FIXX Offer?
- Develops gene therapies for rare genetic diseases.
- Utilizes its proprietary AAVHSc platform for in vivo gene delivery.
- Focuses on both gene therapy and nuclease-free gene editing.
- Targets a range of disease-relevant tissues through single injections.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Seeks regulatory approvals for its gene therapies.
- Commercializes its approved gene therapies.
How Does FIXX Make Money?
- Develops and patents novel gene therapies.
- Conducts research and development to advance its pipeline programs.
- Out-licenses or partners with other companies for commercialization.
- Generates revenue through product sales and licensing agreements.
What Industry Does FIXX Operate In?
Homology Medicines operates within the rapidly evolving biotechnology industry, specifically in the genetic medicine and gene therapy segment. The market for gene therapies is projected to experience substantial growth, driven by advancements in vector technology and increasing regulatory approvals. Competition is intense, with companies like Bluebird Bio and Sarepta Therapeutics also developing gene therapies for rare diseases. Homology Medicines differentiates itself through its AAVHSc platform, which aims to improve the safety and efficacy of gene delivery.
Who Are FIXX's Key Customers?
- Patients suffering from rare genetic diseases.
- Healthcare providers who treat patients with rare genetic diseases.
- Pharmaceutical companies that partner with Homology Medicines for commercialization.
ROE 231%Key Financial Metrics
Return on equity for Homology Medicines, Inc. stands at 230.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 52.2%, showing how much profit it generates from its asset base. FIXX trades at a trailing price-to-earnings ratio of 3.01, below the Healthcare sector average of ~23x. Its free cash flow yield is -16.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 18.5%, the inverse of the P/E and a quick read on earnings relative to price.
Homology Medicines, Inc. (FIXX) Valuation Context
Valued at $3.02M, FIXX is classified as a micro-cap stock. Relative to its peer group, FIXX's quantitative score of 51/100 is below the peer average of 68/100.
Company Profile
Homology Medicines, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bedford, US. The company is led by CEO Paul Alloway. FIXX has traded publicly since 2018.
F-Score 5/9Financial Health
Homology Medicines, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.19 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Homology Medicines, Inc. revenue of about $2.0M for fiscal 2026, with EPS near $-0.94.
FIXX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those with the most knowledge of the company's prospects see value at current levels.
- The social trading community has shown increased optimism regarding Homology Medicines' gene therapy platform, indicating a belief in its long-term potential.
- Positive whispers about potential partnerships or collaborations in the gene therapy space are circulating, fueling bullish sentiment.
- The overall market sentiment towards gene therapy companies has improved, lifting Homology Medicines along with it.
Bear Case
- Despite insider buying, the overall volume remains low, suggesting cautious optimism rather than strong conviction.
- A vocal segment of the community remains skeptical, citing past clinical trial setbacks and the inherent risks of gene therapy development.
- Market perception is sensitive to any negative news in the gene therapy field, creating a potential downside risk for Homology Medicines.
- The company faces significant competition in the gene therapy space, with larger players potentially overshadowing its efforts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FIXX Latest News
-
Stocks That Hit 52-Week Lows Of Monday
· Aug 12, 2019
FIXX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FIXX.
Price Targets
Wall Street price target analysis for FIXX.
FIXX MoonshotScore
What does this score mean?
The MoonshotScore rates FIXX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul Alloway
Unknown
Information about Paul Alloway's background is not available in the provided data. Therefore, I cannot provide details about his career history, education, or previous roles.
Track Record: Information about Paul Alloway's track record is not available in the provided data. Therefore, I cannot provide details about his key achievements, strategic decisions, or company milestones under his leadership.
What Investors Ask About Homology Medicines, Inc. (FIXX) — Healthcare
What does Homology Medicines, Inc. do?
Homology Medicines, Inc. is a genetic medicines company focused on developing treatments for rare genetic diseases. The company utilizes its proprietary AAVHSc platform to deliver genetic medicines in vivo through gene therapy or nuclease-free gene editing. Their lead product candidate, HMI-102, is in Phase 2 clinical trials for the treatment of phenylketonuria (PKU) in adults. The company aims to address unmet medical needs by targeting the underlying genetic causes of rare diseases.
What do analysts say about FIXX stock?
Analyst opinions on Homology Medicines, Inc. (FIXX) are currently unavailable due to the company's market capitalization of $3.02M, which may limit analyst coverage. Key valuation metrics and growth considerations would typically focus on the progress of their clinical trials, particularly the Phase 2 trial for HMI-102, and the potential for regulatory approvals. The success of their AAVHSc platform and pipeline programs are critical factors for future growth.
What are the main risks for FIXX?
The main risks for Homology Medicines, Inc. include the inherent uncertainties of clinical trial outcomes, particularly for HMI-102 and other pipeline programs. Regulatory hurdles and potential delays in obtaining approvals for its gene therapies also pose significant risks. Furthermore, the company faces competition from other companies developing gene therapies for rare diseases. Dependence on raising additional capital to fund its operations and the potential for product liability claims are additional risks to consider.
What are the key factors to evaluate for FIXX?
Homology Medicines, Inc. (FIXX) holds an AI score of 51/100 (moderate). P/E: 3.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does FIXX data refresh on this page?
FIXX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FIXX's recent stock price performance?
Homology Medicines, Inc. (FIXX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AAVHSc platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FIXX overvalued or undervalued right now?
Homology Medicines, Inc. (FIXX) trades at 3.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying FIXX?
Before investing in Homology Medicines, Inc. (FIXX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided data and may be limited.
- Market data may not be real-time.